2016 Schellenberger V. Amunix unveils next-generation immuno-oncologic cancer therapy platform. https://biopharmadealmakers.nature.com. September 2016 edition, B20.
2016 Podust V.N. et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. Journal of Controlled Release 240: 52-66.
2016 Moore W.V. et al. A randomized safety and efficacy study of Somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency. The Journal of Clinical Endocrinology and Metabolism 101(3):1091-1097.
2014 Ding S. et al. Multivalent antiviral XTEN–peptide conjugates with long in vivo half-life and enhanced solubility. Bioconjugate Chemistry 25(7):1351-1359.
2014 Haeckel A. et al. XTEN-Annexin A5: XTEN allows complete expression of long-circulating protein-based imaging probes as recombinant alternative to PEGylation. Journal of Nuclear Medicine 55(3):508-514.
2013 Podust V.N. et al. Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. Protein Engineering, Design & Selection 26(11):743-753.
2013 Yuen K.C.J. et al. A long-acting human growth hormone with delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone deficient adults. The Journal of Clinical Endocrinology and Metabolism 98(6):2595-2603.
2012 Cleland J.L. et al. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life. Journal of Pharmaceutical Sciences 101(8):2744-2754.
2009 Schellenberger V. et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nature Biotechnology 27(12):1186-1190.